R3 Stem Cell

What R3 Stem Cell does

R3 Stem Cell is a privately held regenerative medicine company founded in 2013 and headquartered in Scottsdale, Arizona, that delivers adipose, bone marrow, umbilical cord, amniotic, and MUSE-derived stem cell therapies, as well as exosome, PRP, Power Plasma, Regenerative Trifecta, StemImplant, and microRNA therapies across more than 50 clinical indications spanning musculoskeletal, autoimmune, neurological, cardiovascular, pulmonary, renal, and reproductive conditions. Underlying technology combines autologous and allogeneic biologics processed at cGMP and ISO-certified labs and administered under IRB-approved study protocols that the company describes as exceeding FDA safety testing standards.

The company generates revenue primarily through one-time patient-paid regenerative procedures performed at company-owned and affiliated Centers of Excellence, with pricing ranging from $2,500 to $8,000+ per US procedure and roughly one-third of that at international clinics in Mexico (Tijuana, Cancun, Puerto Vallarta, Mexico City). A secondary recurring stream comes from the Provider Partnership Program, which enrolls independent physicians and clinics into R3's IRB-approved protocols in exchange for marketing support, consultations, booked procedures, and preferred biologics pricing. Ancillary revenue is generated through third-party patient-financing referrals (Lendvious, iFinance Canada) and paid educational products such as the 'Stem Cell Genius' book, while 30+ free consumer guides and a podcast serve as lead-generation funnels.

R3 distributes services through 80+ centers in 8 countries — the USA, Mexico, Philippines, Pakistan, India, Turkey, South Africa, and the UAE — combining a direct-to-consumer sales motion (free consultations, celebrity/athlete ambassadors, content marketing, webinars) with a medical-tourism channel concentrated in Mexico. The company is founder-led by Dr. David Greene (MD, PhD, MBA) and operates with 11–50 employees; it has no disclosed institutional funding, acquisitions, or restructuring activity.

Name

R3 Stem Cell

Legal name

R3 Stem Cell

Website

https://r3stemcell.com

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

11–50 employees

Short description

R3 Stem Cell is a privately held Scottsdale-based regenerative medicine company founded in 2013 that delivers stem cell, exosome, PRP, and microRNA therapies across 80+ centers in 8 countries to patients with musculoskeletal, autoimmune, neurological, and chronic-disease conditions.

Ownership category

akta.pro rank

Product category

Regenerative Medicine Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Health Services (8000), Services-Specialty Outpatient Facilities, Nec (8093), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Stem Cell–Based Regenerative Therapies (HLAAAGAA)

akta.pro secondary industries

Stem Cell Therapies (MSC/iPSC/HSC-derived) (HLAAABAE), Transplantation & Advanced Therapies Pharmaceuticals (incl. Cell & Gene Therapies) (HLAIAAAO), Cell Therapy Clinical Services & Treatment Centers (apheresis, administration, monitoring) (HLAAABAJ)

Keywords

• Regenerative medicine services
• Stem cell therapy
• Exosome therapy
• Platelet rich plasma
• Medical tourism clinics

Headquarters

HQ city

Scottsdale

HQ country

United States

HQ region

North America

Offices5 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Supply Chain, Infrastructure

Revenue model

1. Stem Cell Therapy Procedures: One-time regenerative medicine procedures using stem cells, exosomes, and related biologics. Pricing varies by cell count, treatment type, and geographic location (US vs international). Revenue generated directly from patient payments for procedures at company-owned and affiliated centers.
2. Provider Partnership Program: Recurring revenue from provider network enrollment in IRB-approved study protocols. Includes marketing support, consultations, booked procedures, and preferred product pricing for participating clinics.
3. Financing Services: Third-party financing options for patients through Lendvious (US) and iFinance Canada, providing commission/referral revenue from financing partnerships.
4. Consumer Guides and Educational Materials: Free consumer guides distributed for lead generation, with paid book 'Stem Cell Genius' available for purchase.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels8 records

Core offering

R3 Stem Cell provides regenerative medicine therapies—primarily adipose, bone marrow, umbilical cord, MUSE, and amniotic stem cell injections; exosome therapy; and platelet-rich plasma (PRP)—delivered at 80+ affiliated clinics across 8 countries. Treatments target more than 50 musculoskeletal, neurological, autoimmune, reproductive, cardiovascular, pulmonary, and organ-failure conditions under IRB-approved clinical study protocols, with combination protocols such as the Regenerative Trifecta that layer stem cells, exosomes, PRP, vitamins, and peptides. The company also runs a Provider Partnership Program recruiting independent clinics into its IRB-approved network.

Product overview

R3 Stem Cell is a global leader in regenerative medicine operating over 80 Centers of Excellence across 8 countries. The company offers a comprehensive portfolio of stem cell and regenerative therapies including multiple types of stem cells (Adipose, Bone Marrow, Umbilical Cord, MUSE, Amniotic), Exosome Therapy, PRP Therapy, Power Plasma, Regenerative Trifecta, StemImplant, and MicroRNA Therapy. These treatments target over 50 conditions across musculoskeletal, neurological, autoimmune, cardiovascular, endocrine, and organ failure categories. The company also provides educational resources including the Stem Cell Genius podcast, consumer guides, and an IRB-approved clinical study program. R3 operates through a provider partnership model with clinics in the USA, Mexico, Philippines, Pakistan, India, Turkey, UAE, and South Africa.

Differentiator

Problem solved

Functional benefit

Brands

• Stem Cell Genius: Podcast and book brand featuring Dr. David Greene discussing stem cell science and regenerative medicine.
• R3 Centers of Excellence
• RENEWED

Products and services

• Stem Cell Therapy (Adipose, Bone Marrow, Umbilical Cord, Amniotic) Regenerative medicine injections using adipose (fat-derived), bone marrow derived, umbilical cord, and amniotic stem cells to treat orthopedic, autoimmune, neurological, and organ conditions in adult patients seeking non-surgical alternatives.
• Exosome Therapy Therapy using exosomes derived from mesenchymal stem cells (MSCs) of umbilical cord tissue, delivering proteins, growth factors, signaling lipids, mRNA, and microRNA to reduce inflammation and promote tissue repair in adult patients.
• PRP Therapy (Platelet Rich Plasma) Autologous therapy using the patient's own blood plasma concentrated with platelets and growth factors, injected into problem areas such as knee, shoulder, or hip to promote healing in adult patients with joint and soft tissue conditions.
• MUSE Stem Cells Multipotent Untouched Stem Cell Extraction (MUSE) cells derived from umbilical cord tissue, delivered as a live cell application with 20 or 40 million cells per treatment for regenerative therapy at R3 Mexico clinics.
• Regenerative Trifecta Combined regenerative protocol layering stem cells, exosomes, PRP, vitamins, and peptides in a customized treatment to maximize therapeutic outcomes for adult regenerative medicine patients.
• Power Plasma Enhanced platelet-rich plasma therapy providing additional regenerative benefits beyond standard PRP treatments for joint and soft tissue conditions.
• StemImplant Regenerative implant therapy designed for joint and tissue repair applications in patients needing structural regenerative support.
• MicroRNA Therapy Genetic therapy using microRNAs to regulate cellular functions and promote tissue repair by influencing gene expression in malfunctioning tissues.
• Stem Cell Therapy for Infertility / Premature Ovarian Failure Stem cell and exosome therapy delivered via IV and intra-ovarian approaches for women with premature ovarian failure (POF) and related infertility, offered at international R3 locations.
• R3 Provider Partnership Program All-in-one regenerative practice program for independent physicians and clinics, providing IRB-approved protocols, marketing support, booked procedure flow, and preferred product pricing within R3's global network.
• IRB-Approved Clinical Study Program IRB-approved regenerative therapy research protocols with standardized consent forms and outcome instruments, offered to provider partners and patients across orthopedic, neurologic, urologic, autoimmune, cardiac, renal, and pulmonary conditions.
• Stem Cell Genius Book Consumer book exploring how regenerative therapies work, summarizing research and real patient cases to help readers understand stem cell science.
• Free Consumer Guides (30+) Free downloadable guides covering 30+ conditions including ALS, Arthritis, Autism, Back Pain, Cerebral Palsy, and Diabetes, providing educational information on regenerative therapy options.

Quantifiable outcome

• 85% patient satisfaction rate
• +3 more outcomes

Named customers8 records

Segments6 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Regenexx: Regenexx is the most established US-based direct competitor operating a network of clinics offering autologous stem cell and platelet-rich plasma injections for orthopedic and pain conditions — same product category, same cash-pay model, same target patient base as R3 Stem Cell.
• BioXcellerator: BioXcellerator is a stem cell therapy clinic operating in Colombia and other international locations offering umbilical cord-derived mesenchymal stem cell treatments for orthopedic, autoimmune, and neurological conditions — directly comparable international medical-tourism peer to R3's Mexico operations.
• GIOSTAR: GIOSTAR (Global Institute of Stem Cell Therapy and Research) operates an international network of stem cell treatment centers with a similar direct-to-patient model offering stem cell therapy for orthopedic, neurological, autoimmune, and degenerative conditions — closely comparable to R3's global clinic footprint.
• Swiss Medica: Swiss Medica runs regenerative medicine clinics in Switzerland and abroad offering adult stem cell therapy for chronic and degenerative diseases, including orthopedic, autoimmune, and neurological indications — directly comparable service offering, target patient profile, and international medical-tourism positioning to R3.
• Celltex Therapeutics: Celltex is a Houston-based stem cell company that banks and administers autologous mesenchymal stem cells for therapeutic use, with strong ties to Mexico-based clinical administration — overlapping with R3's autologous/adipose stem cell procedures and its US-to-Mexico treatment pathway.
• StemGenex: StemGenex operates as a US stem cell treatment clinic offering adipose-derived stem cell therapy for a range of conditions including MS, Parkinson's, and osteoarthritis — same cash-pay direct-to-patient regenerative medicine model targeting similar indications as R3 Stem Cell.

Broad incumbents

• Mesoblast: Mesoblast is a publicly traded cell therapy developer with FDA- and EMA-advanced mesenchymal stem cell platforms targeting orthopedic, inflammatory, and cardiovascular indications. It is a broader, regulated alternative operating in the same cellular therapy category that R3's cash-pay treatments effectively compete against once approvals land.
• Organogenesis: Organogenesis is a regenerative medicine incumbent with FDA-approved biologic wound care and orthopedic sports medicine products. It represents a broader, established player in regenerative biologics adjacent to R3's PRP and stem cell orthopedic offering.
• Vericel: Vericel is a commercial-stage cell therapy company with FDA-approved autologous cartilage repair (MACI) and burn skin substitutes — competing in the same orthopedic regenerative niche as R3 but with FDA-approved, insurance-reimbursed products that increasingly constrain R3's cash-pay orthopedic business.

Emerging players

• InGeneron: InGeneron is a clinical-stage regenerative medicine company developing point-of-care adipose-derived stem cell therapies for orthopedic and wound-healing indications. It represents an emerging, technology-focused entrant whose FDA pathway progress directly threatens the same US procedures R3 currently sells on a cash-pay basis.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/stemcellr3
• YouTubeyoutube.com/channel/UCqYMGxtTteHOSmlvAVhNUeA
• Facebookfacebook.com/r3stemcelltherapyofficial
• Instagraminstagram.com/r3stemcellofficial
• TikToktiktok.com/@r3stemcell?lang=en

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about R3 Stem Cell